NEW YORK, July 21, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hum ...

In an unexpected discovery, the analysis revealed an increase in phagocytosis markers in classical monocytes, suggesting that nasal foralumab may enhance their ability to clear amyloid plaques. This ...

Researchers from the University of Florida have created an mRNA vaccine that doesn’t target specific diseases, but instead offers a boost to a person’s immune system. The combination of an immune ...